Newron partners safinamide with Zambon in the US and EU
This article was originally published in Scrip
Executive Summary
Newron has met its previously stated April deadline for securing a partner for its Phase III lead compound, safinamide, by entering into a strategic collaboration and licence option in the EU and US with the small Italian pharmaceutical company Zambon.